File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma

TitlePrognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma
Authors
Issue Date2009
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmccancer/
Citation
Bmc Cancer, 2009, v. 9 How to Cite?
AbstractBackground: Trimethylation of lysine 27 on histone H3 (H3K27me3) by enhancer of zeste homolog 2 (EZH2) is an epigenetic mark that mediates gene silencing. EZH2 is overexpressed and correlates with poor prognosis in many cancers. However, the clinical implication of H3K27me3 in human malignancies has not been well established. We wished to ascertain whether a correlation exists between the expression of H3K27me3 and clinical outcome in a group of patients with esophageal squamous cell carcinoma (ESCC) treated with definitive chemoradiotherapy (CRT).Methods: The method of immunohistochemistry (IHC) was utilized to examine the protein expression of H3K27me3 in 98 pretreatment biopsy specimens of ESCC and in 30 samples of normal esophageal mucosa. The clinical/prognostic significance of H3K27me3 expression was statistically analyzed.Results: The expression frequency and expression levels of H3K27me3 were significantly higher in ESCCs than in normal tissues. There was a positive correlation between H3K27me3 expression and WHO grade (P = 0.016), tumor size (P = 0.019), T status (P = 0.024), locoregional progression (P = 0.009) and EZH2 expression (P = 0.036). High H3K27me3 expression was associated with poor locoregional progression-free survival (LPFS) (P = 0.010) in ESCC. Further analysis demonstrated that H3K27me3 could stratify patient outcome in T2-3 (P = 0.048), N0 (P = 0.005) and M0 (P = 0.018) stages as well as in CRT effective group (P = 0.022).Conclusions: Our data suggests that H3K27me3 expression examined by IHC might be useful for stratifying LPFS for different subsets of ESCC patients treated with definitive CRT. © 2009 He et al; licensee BioMed Central Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/68254
ISSN
2015 Impact Factor: 3.265
2015 SCImago Journal Rankings: 1.627
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
Major State Basic Research Program of China2006CB910104
863 Project of China2007AA021901
Funding Information:

The study was supported by the grants from the Major State Basic Research Program of China (2006CB910104) and the 863 Project of China (2007AA021901)

References

 

DC FieldValueLanguage
dc.contributor.authorHe, LRen_HK
dc.contributor.authorLiu, MZen_HK
dc.contributor.authorLi, BKen_HK
dc.contributor.authorRao, HLen_HK
dc.contributor.authorLiao, YJen_HK
dc.contributor.authorGuan, XYen_HK
dc.contributor.authorZeng, YXen_HK
dc.contributor.authorXie, Den_HK
dc.date.accessioned2010-09-06T06:02:49Z-
dc.date.available2010-09-06T06:02:49Z-
dc.date.issued2009en_HK
dc.identifier.citationBmc Cancer, 2009, v. 9en_HK
dc.identifier.issn1471-2407en_HK
dc.identifier.urihttp://hdl.handle.net/10722/68254-
dc.description.abstractBackground: Trimethylation of lysine 27 on histone H3 (H3K27me3) by enhancer of zeste homolog 2 (EZH2) is an epigenetic mark that mediates gene silencing. EZH2 is overexpressed and correlates with poor prognosis in many cancers. However, the clinical implication of H3K27me3 in human malignancies has not been well established. We wished to ascertain whether a correlation exists between the expression of H3K27me3 and clinical outcome in a group of patients with esophageal squamous cell carcinoma (ESCC) treated with definitive chemoradiotherapy (CRT).Methods: The method of immunohistochemistry (IHC) was utilized to examine the protein expression of H3K27me3 in 98 pretreatment biopsy specimens of ESCC and in 30 samples of normal esophageal mucosa. The clinical/prognostic significance of H3K27me3 expression was statistically analyzed.Results: The expression frequency and expression levels of H3K27me3 were significantly higher in ESCCs than in normal tissues. There was a positive correlation between H3K27me3 expression and WHO grade (P = 0.016), tumor size (P = 0.019), T status (P = 0.024), locoregional progression (P = 0.009) and EZH2 expression (P = 0.036). High H3K27me3 expression was associated with poor locoregional progression-free survival (LPFS) (P = 0.010) in ESCC. Further analysis demonstrated that H3K27me3 could stratify patient outcome in T2-3 (P = 0.048), N0 (P = 0.005) and M0 (P = 0.018) stages as well as in CRT effective group (P = 0.022).Conclusions: Our data suggests that H3K27me3 expression examined by IHC might be useful for stratifying LPFS for different subsets of ESCC patients treated with definitive CRT. © 2009 He et al; licensee BioMed Central Ltd.en_HK
dc.languageengen_HK
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmccancer/en_HK
dc.relation.ispartofBMC Canceren_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic use-
dc.subject.meshCarcinoma, Squamous Cell - diagnosis - drug therapy - metabolism - radiotherapy-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshEsophageal Neoplasms - diagnosis - drug therapy - metabolism - radiotherapy-
dc.subject.meshHistones - metabolism-
dc.titlePrognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1471-2407&volume=9 article no. 461&spage=&epage=&date=2009&atitle=Prognostic+impact+of+H3K27me3+expression+on+locoregional+progression+after+chemoradiotherapy+in+esophageal+squamous+cell+carcinoma.en_HK
dc.identifier.emailGuan, XY:xyguan@hkucc.hku.hken_HK
dc.identifier.authorityGuan, XY=rp00454en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/1471-2407-9-461en_HK
dc.identifier.pmid20028503-
dc.identifier.pmcidPMC2804715-
dc.identifier.scopuseid_2-s2.0-74249098871en_HK
dc.identifier.hkuros169986en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-74249098871&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume9en_HK
dc.identifier.isiWOS:000273840300002-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridHe, LR=35069492500en_HK
dc.identifier.scopusauthoridLiu, MZ=35285929300en_HK
dc.identifier.scopusauthoridLi, BK=26663761000en_HK
dc.identifier.scopusauthoridRao, HL=35277843000en_HK
dc.identifier.scopusauthoridLiao, YJ=36114448500en_HK
dc.identifier.scopusauthoridGuan, XY=7201463221en_HK
dc.identifier.scopusauthoridZeng, YX=7402981579en_HK
dc.identifier.scopusauthoridXie, D=35070710200en_HK
dc.identifier.citeulike6446686-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats